TTP-8307

TTP-8307 is a potent inhibitor of the replication of several rhino- and enteroviruses. TTP-8307 inhibits coxsackievirus B3 (CVB3; EC50=1.2 μM) and poliovirus by interfering with the synthesis of viral RNA. TTP-8307 exerts antiviral activity through oxysterol-binding protein (OSBP) [1][2].

Product Specifications

CAS Number

950225-08-8

UNSPSC

12352005

Target

DNA/RNA Synthesis; Enterovirus; HCV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ttp-8307.html

Purity

99.90

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](C1=CC=C(F)C=C1)C)C2=CC=CC(C3=CN=C(C4=CC5=C(C=N4)C=CC=C5)N3)=C2

Molecular Formula

C27H21FN4O

Molecular Weight

436.48

References & Citations

[1]De Palma AM, et al. Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307. Antimicrob Agents Chemother. 2009 May;53 (5) :1850-7.|[2]Albulescu L, et al. Uncovering oxysterol-binding protein (OSBP) as a target of the anti-enteroviral compound TTP-8307. Antiviral Res. 2017 Apr;140:37-44.